- New development to stimulate innovation
- Shared focus on technology and application of probiotic solutions
- More sustainable, efficient and environmentally-friendly aquaculture
New agreement expands deal signed in November 2018.
Evonik and Vland have signed a Joint Development Agreement (JDA) as part of their existing broader partnership in the field of probiotics for animal nutrition and enzymes for industrial applications.
The combination of Vland’s core production technology and Evonik’s strong global market presence – as well as the shared focus on technology and application of probiotic solutions – is expected to bring mutual benefits to both partners, including new product developments.
“The JDA is expected to stimulate innovation and joint R&D activities in the field of selection, production, formulation and application of our new probiotic solution,” says Dr. Emmanuel Auer, head of Evonik’s Animal Nutrition Business Line.
“Evonik is excited to partner with Vland in this joint initiative to develop the next probiotic solution focusing on a more sustainable, efficient and environmentally-friendly production,” he added.
“Based on years’ cooperation, Vland and Evonik extend the scope to plant, livestock and aquaculture in the solution of probiotics products. After IPO, Vland focus on R&D and globalization, and strive to become a technology-driven enterprise,” says Aron Chen, CEO of Vland.
Vland Biotech has been established in 2005. Headquartered in Qingdao in the Shandong Province of China, the company has a current headcount of just over 1,300 employees. Vland specializes in the research and development of four main product categories which are enzymes, probiotics, vaccines and animal health products. The company is dedicated to the provision of core technological support for bio-manufacturing, green solutions for food safety, and clean and energy-saving technologies to traditional industries. Vland is able to provide solutions to an ever-expanding list of industries including agriculture, animal husbandry, textile, paper making, household cleaning and detergents, food, biofuel, environmental protection and more.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2018, the enterprise generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.6 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around
€4.6 billion in 2018.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.